Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of grazoprevir + elbasvir in treatment-naive chronic hepatitis C patients on opiate substitution therapy
NL-OMON42051Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of grazoprevir and elbasvir in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoints: SVR12, Safety and tolerability and 1 more. Started Sep 2014; status: active, not recruiting.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON42051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42051.